{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:31:49Z","timestamp":1793475109336,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jhepr.2026.102038","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:37:06Z","timestamp":1789861026000},"page":"102038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-3953","authenticated-orcid":false,"given":"Jaclyn","family":"Neely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-459X","authenticated-orcid":false,"given":"Jin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-3474","authenticated-orcid":false,"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2494-2126","authenticated-orcid":false,"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6417","authenticated-orcid":false,"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony B.","family":"El-Khoueiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rosmorduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Tschaika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan","family":"Novosiadly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-2430","authenticated-orcid":false,"given":"Robin Kate","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jhepr.2026.102038_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2026.102038_bib2","unstructured":"National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Liver intrahepatic bile duct cancer. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html (accessed December 14, 2024)."},{"issue":"4","key":"10.1016\/j.jhepr.2026.102038_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.annonc.2023.12.008","article-title":"Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040","volume":"35","author":"El-Khoueiry","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jhepr.2026.102038_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102038_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jhepr.2026.102038_bib6","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1078-0432.CCR-21-3807","article-title":"Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial","volume":"28","author":"Verset","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jhepr.2026.102038_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.jhepr.2026.102038_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102038_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jhepr.2026.102038_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Martinez-Jimenez","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102038_bib11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.jhepr.2026.102038_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.jhepr.2026.102038_bib13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Wheeler","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.jhepr.2026.102038_bib14","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jhepr.2026.102038_bib15","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102038_bib16","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jhepr.2026.102038_bib17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"10183","key":"10.1016\/j.jhepr.2026.102038_bib18","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"35","key":"10.1016\/j.jhepr.2026.102038_bib19","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jhepr.2026.102038_bib20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102038_bib21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.jhepr.2026.102038_bib22","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1002\/cncr.32339","article-title":"Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma","volume":"125","author":"Feun","year":"2019","journal-title":"Cancer"},{"issue":"7559","key":"10.1016\/j.jhepr.2026.102038_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.102038_bib24","series-title":"survminer: survival analysis and visualization","author":"Kassambara","year":"2019"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102038_bib25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under Dependency","volume":"29","author":"Benjamini","year":"2001","journal-title":"Ann Stat"},{"issue":"10","key":"10.1016\/j.jhepr.2026.102038_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"7463","key":"10.1016\/j.jhepr.2026.102038_bib27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102038_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"23","key":"10.1016\/j.jhepr.2026.102038_bib29","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"6230","key":"10.1016\/j.jhepr.2026.102038_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102038_bib31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102038_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"issue":"D1","key":"10.1016\/j.jhepr.2026.102038_bib33","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102038_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061502","article-title":"Combined PARP inhibition and immune checkpoint therapy in solid tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2026.102038_bib35","article-title":"Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors","volume":"10570","author":"Vikas","year":"2020","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.jhepr.2026.102038_bib36","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.jhepr.2026.102038_bib37","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jhepr.2026.102038_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004761","article-title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","volume":"10","author":"Fizazi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2026.102038_bib39","article-title":"Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis","volume":"14117","author":"Xiao","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.102038_bib40","article-title":"Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy","volume":"11212","author":"Ma","year":"2013","journal-title":"World J Surg Oncol"},{"issue":"12","key":"10.1016\/j.jhepr.2026.102038_bib41","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/ijc.28311","article-title":"Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments","volume":"133","author":"Lee","year":"2013","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102038_bib42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00018-022-04226-0","article-title":"Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types","volume":"79","author":"Willumsen","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"10.1016\/j.jhepr.2026.102038_bib43","article-title":"The extracellular matrix in hepatocellular carcinoma: mechanisms and therapeutic vulnerability","volume":"4","author":"Roy","year":"2023","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102038_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050935","article-title":"Collagen type XI alpha 1 (COL11A1): a novel biomarker and a key player in cancer","volume":"13","author":"Nallanthighal","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102038_bib45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ijc.33551","article-title":"Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenocarcinoma","volume":"149","author":"Nissen","year":"2021","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102038_bib46","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.canlet.2014.12.011","article-title":"Tumor matrix protein collagen XI\u03b11 in cancer","volume":"357","author":"Raglow","year":"2015","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102038_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12876-025-03645-0","article-title":"Collagen turnover biomarkers to predict outcome of patients with biliary cancer","volume":"25","author":"Kaps","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102038_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbplus.2022.100101","article-title":"Uncovering mediators of collagen degradation in the tumor microenvironment","author":"Thorseth","year":"2022","journal-title":"Matrix Biol Plus"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102038_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13046-019-1110-6","article-title":"Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology","volume":"38","author":"Nissen","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102038_bib50","article-title":"Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer","volume":"9","author":"Willumsen","year":"2019","journal-title":"Scientific Rep"},{"key":"10.1016\/j.jhepr.2026.102038_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100788","article-title":"Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis","author":"Deng","year":"2022","journal-title":"Neoplasia"},{"issue":"8","key":"10.1016\/j.jhepr.2026.102038_bib52","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102038_bib53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jhepr.2026.102038_bib54","article-title":"965MO Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW","volume":"35","author":"Decaens","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 17","key":"10.1016\/j.jhepr.2026.102038_bib55","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW","volume":"42","author":"Galle","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102038_bib56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13561-024-00526-2","article-title":"Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review","volume":"14","author":"Gong","year":"2024","journal-title":"Health Econ Rev"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102038_bib57","first-page":"590","article-title":"Risk of bleeding in hepatocellular carcinoma patients treated with atezolizumab\/bevacizumab: a systematic review and meta-analysis","volume":"13","author":"Song","year":"2024","journal-title":"Liver Cancer"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102038_bib58","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926003095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926003095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:08:02Z","timestamp":1793473682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926003095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2589555926003095"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102038","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102038"}}